Aging with Crohn's Disease: What Older Patients Need to Know

Whether you have been managing Crohn's disease for decades or received a surprising new diagnosis after age 60, aging with Crohn's disease brings a unique set of challenges that most IBD resources simply do not address. The older adult IBD population is growing faster than any other age group, and the medical community is finally paying attention. This article explores what makes Crohn's different in later life - from diagnostic blind spots to treatment decisions, polypharmacy pitfalls, insurance transitions, and the emotional reality of living with a chronic illness as you age.

Key Takeaways

• Adults over 60 now represent roughly 30% of the IBD population in countries like the UK and Canada, and projections suggest one in three IBD patients will be over 60 by 2030 (2)(3)
• Misdiagnosis occurs in up to 60% of elderly IBD patients compared with just 15% of younger patients, with diagnostic delays as long as 6 years (4)
• After 52 weeks of anti-TNF therapy, clinical remission was only 37.7% in elderly-onset patients vs. 60.8% in younger patients (6)
• Older patients are frequently undertreated due to fear of side effects, yet modern guidance emphasizes biological age and frailty over chronological age when choosing therapy (5)
• A coordinated care team including a geriatrician, gastroenterologist, and pharmacist can reduce harmful drug interactions from polypharmacy (5)

The Growing Population of Older Adults with Crohn's Disease

Older adults are the fastest-growing segment of the IBD population worldwide. About 30% of people with IBD in countries like the UK and Canada are now over 65 - up from less than 20% in 2010 (3). By 2030, projections suggest that one in three IBD patients will be over 60 (2). A 2021 analysis of 23 million U.S. adults aged 67 and older found that Crohn's disease prevalence was increasing by 3.4% per year and ulcerative colitis by 2.8% per year (8).

Two distinct groups: aging with IBD vs. elderly-onset disease

This growing population includes two distinct groups with different concerns. The first are long-time IBD veterans who received their diagnosis in their 20s or 30s and are now aging into their 60s and 70s. They carry cumulative effects of years of inflammation, medications, and surgeries. The second group are patients newly diagnosed after age 60 - elderly-onset IBD accounts for about 13% of all IBD cases worldwide (1). Each group faces overlapping but distinct challenges in managing their disease.

Why incidence is rising in seniors

Several forces drive this trend. Improved treatments mean more patients are living longer with their disease. At the same time, genuine new-onset IBD in older adults is increasing - likely due to shifts in environmental exposures, dietary changes, microbiome disruption from medications like antibiotics and NSAIDs, and the natural age-related decline in immune regulation known as immunosenescence (1)(3).

How Crohn's Disease Looks Different in Older Adults

For older adults, Crohn's disease is not simply the same illness at a later age. The biology, presentation, and diagnostic journey differ in ways that matter for treatment and outcomes. Late-onset Crohn's often has a more colonic, less stricturing phenotype, but delayed diagnosis can still lead to serious complications (3).

Unique biology: less genetic, more aging-driven

In younger patients, strong genetic predisposition (particularly NOD2/CARD15 variants) plays a central role. In elderly-onset Crohn's, genetics contribute less. Instead, immunosenescence - the gradual decline in immune function with age - and gut dysbiosis (an imbalance of intestinal bacteria) play larger roles in triggering disease (1). This means the disease pathways differ, which has implications for which treatments work best.

Diagnostic pitfalls and delays

One of the most concerning findings in the research is how often Crohn's disease is missed or misdiagnosed in older adults. Misdiagnosis occurs in up to 60% of elderly IBD patients, compared with about 15% of younger patients, and diagnosis can be delayed by as long as 6 years (4). Conditions commonly confused with IBD in seniors include diverticular disease, ischemic colitis, NSAID-associated diarrhea, microscopic colitis, and infectious colitis. Making matters more difficult, fecal calprotectin - a standard screening tool - is less reliable in older adults, with one report finding only a 23.1% positive predictive value above 200 micrograms per gram (2).

If you are over 60 and experiencing persistent diarrhea, abdominal pain, weight loss, or rectal bleeding, do not let these symptoms be dismissed as "just aging." Ask your doctor whether IBD should be considered in the differential diagnosis.

Treatment Considerations: Balancing Efficacy and Safety

Choosing the right treatment for Crohn's disease in older adults involves weighing benefits and risks differently than in younger patients. The stakes are higher on both sides - undertreating leads to complications and disability, while some medications carry greater absolute risks in aging bodies.

Why frailty matters more than chronological age

Modern gastroenterology guidance emphasizes that biological age and frailty should drive treatment decisions, not the number on a birthday card (1)(5). A fit, active 72-year-old and a frail 65-year-old with multiple comorbidities require very different approaches. Frailty assessments consider factors like grip strength, walking speed, weight loss, exhaustion, and physical activity level. Fit older patients should not be denied effective therapy based solely on age.

Risks of common IBD medications in seniors

That said, older IBD patients do face higher absolute rates of serious infections, hospitalizations, herpes zoster (shingles), fractures, venous thromboembolism, and certain cancers (5). These risks are real and deserve careful monitoring. Anti-TNF therapies show lower efficacy in elderly-onset patients - after 52 weeks of anti-TNF therapy, clinical remission was 37.7% in elderly-onset patients vs. 60.8% in younger patients, and steroid-free remission was 35.9% vs. 57.8% (6).

Newer biologics such as vedolizumab (gut-selective, meaning it targets the intestine rather than suppressing the whole immune system) and ustekinumab may offer better safety profiles for some older adults, though more research specifically in elderly populations is needed (5).

The undertreatment problem

Perhaps the biggest treatment challenge is not side effects - it is undertreatment. Too many older patients are kept on long-term corticosteroids and denied advanced therapies out of an excessive fear of complications (5). Long-term steroids carry their own devastating consequences in older bodies: osteoporosis and fractures, diabetes, cataracts, muscle wasting, and increased infection risk. If your doctor seems reluctant to step beyond steroids, it is reasonable to ask whether a biologic or targeted therapy might actually be safer for you in the long run.

Managing Comorbidities and Polypharmacy

As we age, most of us accumulate additional health conditions and the medications that come with them. For Crohn's patients, this creates a complex web of interactions that requires careful coordination.

The polypharmacy challenge

Among adults aged 57 to 85, about 29% take five or more prescription medications, and 4% are at risk of major drug-drug interactions (5). When you add IBD medications - immunosuppressants, biologics, or targeted small molecules - to an existing list of blood pressure pills, diabetes medications, cholesterol drugs, and perhaps blood thinners, the potential for harmful interactions rises significantly. Some common medications like NSAIDs (ibuprofen, naproxen) can trigger IBD flares, yet they are frequently prescribed for age-related arthritis without considering their gut effects.

Cancer screening and bone health

Older Crohn's patients should discuss regular screening for colorectal cancer, skin cancer (especially with long-term immunosuppression), anemia, osteoporosis, eye health, and arthritis with their care team (7). Bone density testing (DEXA scans) is especially important if you have had significant steroid exposure over the years. Cardiovascular risk assessment is also wise, as chronic inflammation contributes to heart disease.

Building a coordinated care team

A multidisciplinary approach works best: a geriatrician or primary care physician who acts as a "quarterback," a gastroenterologist familiar with IBD in older adults, and a pharmacist who reviews all medications for interactions (5)(7). This team-based model reduces the chance that one specialist prescribes something that conflicts with another's treatment plan. If you are managing Crohn's alongside other conditions, consider asking for a comprehensive medication review at least once a year.

Insurance, Medicare, and Practical Planning

For those aging with Crohn's disease in the United States, the transition to Medicare at age 65 is a significant financial and logistical event. For readers in other countries, equivalent transitions (such as changes in public coverage or pension-related healthcare shifts) deserve similar advance planning. We covered broader strategies in our financial planning guide, but there are specific considerations for older IBD patients.

Preparing for the Medicare transition at 65

Patients approaching 65 should research how Medicare Part B (which covers infusions administered in a clinic or hospital) and Part D (which covers oral medications and self-injected biologics) apply to their specific treatment regimen (7). The difference between these two parts can mean thousands of dollars in out-of-pocket costs depending on whether your biologic is infused or self-injected.

Comparing Original Medicare with Medicare Advantage plans before your 65th birthday enrollment window helps avoid coverage gaps and unexpected provider changes. Some Advantage plans offer lower premiums but restrict which infusion centers or specialists you can see - a serious concern if you have an established relationship with your gastroenterologist.

Coverage gaps for biologics and infusions

Supplemental Medigap plans can offset out-of-pocket costs for frequent infusions or surgeries. If you rely on a biologic, factor in the "donut hole" in Part D coverage and investigate manufacturer patient assistance programs that may bridge gaps.

Beyond insurance, practical documentation matters: prepare advance directives, designate a durable power of attorney for healthcare decisions, and maintain a current written medication list that includes all prescriptions, over-the-counter drugs, and supplements. Share copies with family members and keep one accessible in case of emergency.

Quality of Life: Emotional and Social Realities

The practical challenges of aging with Crohn's disease are intertwined with emotional and social realities that deserve equal attention. For women navigating both menopause and IBD, hormonal shifts can add another layer of complexity to an already demanding situation.

Loneliness, identity, and aging with a chronic illness

Many older patients face social isolation - from losing peers, from retirement removing a daily social structure, or from flares that limit travel and activities. The combination of aging and chronic illness can trigger a genuine identity shift: Who am I now that I cannot do what I used to? How do I plan for the future when my disease is unpredictable?

This kind of identity work - rethinking purpose, exploring new hobbies within physical limits, accepting change without surrendering to it - is part of healthy aging with a chronic illness, not a sign of giving up. It takes courage and honesty, and it often benefits from the perspective of others walking the same path.

Connecting with peers and support resources

You are not alone in this. The Crohn's & Colitis Foundation runs a dedicated IBD Seniors Virtual Support Group on the second Tuesday of each month, specifically for patients aged 60 and older (7). Their resource hub provides information tailored to the concerns of older IBD patients. Online communities, local support groups, and even one-on-one peer mentoring programs can help combat isolation.

Caregiver support and honest family communication become more important as physical reserves decline. If you have adult children or a partner involved in your care, including them in medical appointments (when you are comfortable) ensures everyone understands the plan and can advocate for you when needed.

Moving Forward with Confidence

Aging with Crohn's disease is not a sentence to decline - it is a call to adapt with the same resilience that got you through every flare before this one. The research is clear that older adults deserve, and benefit from, the same evidence-based treatments available to younger patients. Advocate for yourself, build a coordinated care team, stay current on your screenings, and connect with others who truly understand what this journey looks like after 60.

Frequently Asked Questions

Is Crohn's disease harder to diagnose in older adults?

Yes. Research shows that misdiagnosis occurs in up to 60% of elderly IBD patients, compared with about 15% of younger patients (4). Symptoms of Crohn's overlap with many age-related conditions including diverticular disease and ischemic colitis. If you have persistent digestive symptoms, ask your doctor specifically about IBD.

Should older patients avoid biologic therapies?

Not automatically. Modern guidance emphasizes that treatment decisions should be based on biological age and overall frailty rather than chronological age alone (1)(5). A fit older adult should not be denied effective therapy simply because of their age. Discuss the specific risks and benefits with your gastroenterologist.

What medications interact badly with IBD drugs in older adults?

NSAIDs (like ibuprofen and naproxen) are common culprits - they can trigger flares and are frequently prescribed for arthritis in seniors. Blood thinners, certain antibiotics, and some cardiovascular medications may also interact with IBD treatments. A pharmacist-led medication review can identify problematic combinations (5).

How does Medicare cover biologic treatments for Crohn's?

In the U.S., Medicare Part B typically covers biologics administered by infusion in a clinical setting, while Part D covers self-injected and oral biologics (7). Coverage details, copays, and the "donut hole" vary by plan. Research your specific medication's coverage before turning 65 to avoid surprises.

Are there support groups specifically for older adults with IBD?

Yes. The Crohn's & Colitis Foundation offers a dedicated IBD Seniors Virtual Support Group that meets on the second Tuesday of each month for patients aged 60 and older (7). Online communities and local gastroenterology practices may also offer age-specific resources.

Why do anti-TNF drugs work less well in older patients?

Research found clinical remission rates of only 37.7% in elderly-onset patients vs. 60.8% in younger patients after 52 weeks of anti-TNF therapy (6). The reduced efficacy likely relates to differences in immune function with aging (immunosenescence) and different underlying disease mechanisms in late-onset IBD. Alternative biologics like vedolizumab or ustekinumab may be considered (5).

What screening tests should older Crohn's patients prioritize?

Older patients should discuss regular screening for colorectal cancer, skin cancer (especially with immunosuppressive therapy), bone density (DEXA scans), anemia, eye health, and cardiovascular risk with their care team (7). The specific schedule depends on your treatment history and individual risk factors.

References

1. Mak, J.W.Y., et al. Crohn's Disease of the Elderly: Unique Biology and Therapeutic Efficacy and Safety. Inflammatory Bowel Diseases, 2022. Read study
2. Defined Research Group. The management of small bowel Crohn's disease in older age. 2025. Read study
3. Defined Research Group. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies. 2024. Read article
4. Defined Research Group. Management of inflammatory bowel disease in the elderly: A review. Digestive and Liver Disease, 2022. Read article
5. American Gastroenterological Association. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. 2021. Read guidance
6. Defined Research Group. Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease. Scientific Reports, 2022. Read study
7. Crohn's & Colitis Foundation. Aging with IBD. 2024. Visit resource
8. Harvard Health Publishing. Inflammatory bowel disease on the rise in older adults. 2021. Read article